Eli Lilly invests $4.5B in Lilly Medicine Foundry for drug development and manufacturing.

Eli Lilly & Co is investing $4.5 billion in the Lilly Medicine Foundry, a new facility focused on enhancing drug development and manufacturing efficiency. This initiative follows the success of its GLP-1 obesity treatments, Mounjaro and Zepbound, projected to generate nearly $19 billion by 2024. The facility will also support research for conditions like Alzheimer's and ALS. Despite short-term stock market challenges, the company’s long-term outlook remains positive.

October 02, 2024
52 Articles